| Nov 5 |
Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting
|
| Oct 31 |
Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Madrid, Spain
|
| Oct 16 |
Vaccinex files for secondary stock offering
|
| Sep 18 |
What's Going On With Vaccinex Stock Wednesday?
|
| Sep 18 |
Vaccinex exercises warrants for proceeds of $6.2M
|
| Sep 18 |
Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds
|
| Aug 14 |
Vaccinex says Alzheimer's candidate buoyed by additional early-stage data
|
| Aug 14 |
Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease and Plans to Pursue a Development Partnership
|
| Aug 2 |
Around $3M Bet On This Energy Stock? Check Out These 3 Stocks Insiders Are Buying
|
| Jul 17 |
Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease at the Alzheimer’s Association International Conference, Philadelphia, July 31, 2024
|
